<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04375306</url>
  </required_header>
  <id_info>
    <org_study_id>9333</org_study_id>
    <nct_id>NCT04375306</nct_id>
  </id_info>
  <brief_title>Resting Full-cycle Flow Ratio (RFR) Versus Angiography to Guide Revascularization Strategy in Patients Undergoing Coronary Artery By-pass Grafting (CABG)</brief_title>
  <acronym>RFR-CABG</acronym>
  <official_title>Resting Full-cycle Flow Ratio (RFR) Versus Angiography to Guide Revascularization Strategy in Patients Undergoing Coronary Artery By-pass Grafting (CABG): RFR-CABG Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diagram B.V.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diagram B.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Different trials have shown that fractional flow reserve (FFR) could successfully guide
      revascularization in patients undergoing percutaneous coronary intervention (PCI).

      It is conceivable that a similar revascularization guidance could be useful also for surgical
      revascularization i.e. coronary by-pass graft (CABG). Experience learns that grafts placed on
      vessels with hemodynamically non-significant stenosis often occlude due to competitive
      antegrade flow.

      Resting full-cycle Flow Ratio (RFR) is a measurement performed to evaluate the hemodynamic
      severity of coronary stenosis. Differently from FFR which is a measurement performed in
      maximal hyperemia, the RFR is a measurement that is performed in rest and therefore may
      predict better than FFR the baseline equilibriums that could lead to graft failure, while it
      has similar capacity to identify hemodynamically significant stenosis as FFR. It is unknown
      whether RFR guided CABG revascularization is superior as compared to angiography alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>International prospective randomized multicenter superiority trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients in both arms. In the control arm (angiography guided CABG) the RFR values will be blinded to the cardiothoracic surgeon.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who deceased, had a Myocardial Infarction (MI), Clinically-Driven Target Vessel Revascularization (CD-TVR), Stroke or Graft Dysfunction at 3 months post CABG</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cut-off value for the RFR that best predicts graft occlusion</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with graft dysfunction at 3 months post CABG</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac or cerebrovascular event (MACCE), a composite of Death, MI, CD-TVR and Stroke at 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac or cerebrovascular event (MACCE), a composite of Death, MI, CD-TVR and Stroke at 3 years</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD-TVR at 3 months post CABG</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD-TVR at 1 year post CABG</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD-TVR at 3 years post CABG</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>angiography guided CABG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>angiography guided CABG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RFR guided CABG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RFR guided CABG</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RFR guided CABG</intervention_name>
    <description>All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the experimental arm the decision to revascularize will be based on RFR.</description>
    <arm_group_label>RFR guided CABG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Angio guided CABG</intervention_name>
    <description>All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the control arm the RFR values will be blinded to the cardiothoracic surgeon.</description>
    <arm_group_label>angiography guided CABG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients between 18 or older undergoing CABG

          -  Patients willing and capable to provide written informed consent

        Exclusion Criteria:

          -  Previous CABG

          -  Concomitant severe valvular disease intervention

          -  Remaining (expected) coronary stenosis of &gt; 50% diameter stenosis distally to graft
             anastomosis

          -  Left ventricular ejection fraction &lt;30%

          -  Known transmural myocardial infarction

          -  Documented microvascular disease

          -  RFR/FFR measurement judged impossible

          -  Life expectancy &lt;2 years

          -  Participation in other investigational clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Prof. E. Kedhi, MD, PhD</last_name>
    <phone>+32 50 45 26 71</phone>
    <email>Elvin.Kedhi@azsintjan.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>S. Postma, PhD</last_name>
    <phone>+31 38 426 2999</phone>
    <email>rfrcabg.trial@diagram-zwolle.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. E Kedhi, MD, PhD</last_name>
      <phone>+32 50 45 26 71</phone>
      <email>Elvin.Kedhi@azsintjan.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 1, 2020</study_first_submitted>
  <study_first_submitted_qc>May 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RFR guided CABG</keyword>
  <keyword>angiography guided CABG</keyword>
  <keyword>Graft dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>This has not been decided yet.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

